BioNTech agreed to acquire CureVac for $1.25 billion in an all-stock transaction resolving pending patent litigation and enhancing BioNTech’s manufacturing and oncology pipeline. The deal positions BioNTech to leverage CureVac’s technology and facilities, strengthening its pursuit of mRNA-based cancer therapies and mitigating significant royalty risks from ongoing patent disputes.